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Previewsrodent studies) to neuroscience. A door
has been opened by Evrard et al. (2012),
but much exciting work remains to be
done.
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N-methyl-D-aspartate (NMDA) receptor activation can be neuroprotective or neurotoxic depending on
receptor location. In this issue of Neuron, Martel et al. (2012) demonstrate that the C-terminal of NMDA
receptor subunits also contributes critically to excitotoxicity. NMDA receptor subunits containing the GluN2B
C-terminal are more lethal than those containing the GluN2A tails, regardless of location.Is the location of N-methyl-D-aspartate
receptors (NMDARs) at synaptic or extra-
synaptic sites the only, or even the
primary, determinant of neuroprotective
or neurotoxic effects of glutamate? While
we thought this question had been
settled, at least partially (Levine et al.,
2010; Milnerwood et al., 2010; Okamoto
et al., 2009), newwork from the laboratory
that raised into prominence the differen-
tial role of synaptic and extrasynaptic
NMDARs and gave us a better under-
standing of the intracellular cascades
that lead to excitotoxicity (Hardingham
et al., 2002) now demonstrates that we
were missing part of the equation, a little
but important C-tail. In effect, the
C-terminal domain (CTD) of the NMDAR
subunit appears to play a critical role in
the function of the receptor.
In an elegant study published in this
issue ofNeuron, Martel et al. (2012) reportthat the activation of proapoptotic
cascades is determined not just by the
location of the NMDAR, but also by the
identity of the CTD. As pharmacological
approaches commonly used to differen-
tiate the two subunits are limited at best,
the authors used genetic manipulations
to engender chimeric receptors in which
only the CTD from GluN2A and GluN2B
receptor subunits is C-terminal replaced
(CTR). Why focus on the CTD? It has
been shown that the CTD of NMDAR
subunits is the primary area of sequence
divergence, and it is the site that primarily
binds scaffolding proteins, providing
a strong rationale for examining its role
in excitotoxicity.
In the first series of experiments,
expression of chimeric GluN2B2A(CTR)
receptors in transfected hippocampal
neurons produced similar currents as
wild-type (WT) subunits (GluN2BWT) anddid not affect the proportion of synaptic
and extrasynaptic receptors, thus pre-
venting potential confounds arising from
receptor location. Interestingly, NMDA-
induced cell death was reduced in
chimeric GluN2B2A(CTR) compared to
GluN2BWT-containing receptors, sug-
gesting that excitotoxicity is better
promoted by CTD2B than CTD2A. Simi-
larly, neurons expressing GluN2A2B(CTR)
were more susceptible to cell death than
neurons expressing GluN2AWT (Figure 1).
Using a different approach, a knockin
mouse was generated in which the
protein-coding region of the C-terminal
exon of the GluN2B subunit was
exchanged for that of theGluN2A subunit,
named GluN2B2A(CTR)/2A(CTR). Cultured
cortical neurons from these mice dis-
played similar levels of viability, synaptic
connectivity, proportion of extrasynaptic
NMDARs, sensitivity to ifenprodil,
Figure 1. The C-Terminal Domain of GluN2B Subunits Is More Lethal
Excess glutamate can be excitotoxic via NMDARs. However, the extent of cell
death depends in part on the CTD of NMDAR subunits. Swapping the CTD
from GluN2A for GluN2B produces more cell death. Conversely, swapping
the CTD from GluN2B for GluN2A reduces cell death. Similarly, cells from
genetically modified knockin mice, in which the CTD from GluN2B is replaced
by the CTD ofGluN2A, are less vulnerable than cells fromGluN2B+/+mice, due
in part to increased phosphorylation of CREB. In contrast, CTD2B displays
stronger coupling to the PSD-95/nNOS pathway, which suppresses CREB
activation. This indicates that the GluN2B subunit, regardless of location at
synaptic or extrasynaptic sites, is more lethal than the GluN2A subunit.
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Previewsrundown of NMDA currents,
and single channel conduc-
tance, compared to those
from GluN2B+/+ mice.
Notwithstanding these simi-
larities, NMDA currents
were about 30% lower in
GluN2B2A(CTR)/2A(CTR) than in
GluN2B+/+ cells. By adjusting
exogenous NMDA concen-
trations to produce similar
currents in both types of
cells, the authors confirmed
that normalized NMDA
current produced more
death in GluN2B+/+ than in
GluN2B2A(CTR)/2A(CTR) cells. In
consequence, a switch in the
mouse genome from GluN2B
CTD for GluN2A reduces
NMDA-dependent Ca2+ influx
and excitotoxicity. However,
these differences only
occurred at moderate (15–
50mM)NMDAconcentrations.
When NMDA concentrationwas increased (e.g., 100 mM), the CTD
subtype-specific vulnerability disap-
peared. These results were confirmed
in vivo. Thus, excitotoxic lesions induced
by stereotaxic injection of a small dose of
NMDA into the hippocampus (CA1-CA3
region) induced smaller lesion volumes
in GluN2B2A(CTR)/2A(CTR) compared to
GluN2B+/+ mice.
Which signaling cascades contribute
to differential susceptibility of CTDs to
excitotoxic insults? One obvious target,
based on previous work by Hardingham’s
and other groups, is NMDA-dependent
activation of CREB. While basal levels of
CREB (serine 133) phosphorylation
were unaltered in GluN2B2A(CTR)/2A(CTR)
compared to GluN2B+/+ neurons, CREB
phosphorylation was prolonged in
GluN2B2A(CTR)/2A(CTR) neurons when chal-
lenged with NMDA. This observation was
supported by the fact that blockade of
CRE-mediated gene expression (with
ICER, an inhibitory CREB family member)
increased NMDA-induced cell death, indi-
cating that differential CREB activation
contributes to CTD subtype-dependent
regulation of excitotoxicity.
What makes the two CTDs different?
The answer appears to rely, in part, on
enhanced coupling of CTD2B to the
PSD-95/nNOS signaling cassette. It isknown that nitric oxide (NO) is a key
regulator of CREB phosphorylation. NO
is produced when NMDAR-dependent
Ca2+ influx activates nNOS via PSD-95
association with GluN2 subunits. In addi-
tional experiments, Martel et al. (2012)
found that GluN2B+/+ neurons coupled
more strongly to NMDA-induced NO
production and concluded that stronger
CTD2B coupling to PSD-95, NO produc-
tion, and nNOS-dependent CREB inacti-
vation leads to enhanced vulnerability to
excitotoxic insults. Finally, the basis for
the stronger association of PSD-95 with
GluN2BWT compared to GluN2B2A(CTR)
was explored. An internal region of the
CTD2B (1086–1157), when deleted, re-
sulted in a decrease in PSD-95 asso-
ciation, whereas overexpression of this
region led to reduced NMDA-induced
cell death. This region thus could be impli-
cated in NMDAR signaling leading to cell
death.
The idea that GluN2A and GluN2B
subunits play different roles in diverse
processes such as synaptic plasticity,
intracellular signaling, and excitotoxicity
has often been entertained. In the
case of synaptic plasticity, experimental
evidence is not conclusive, and it appears
that both subunits are necessary (Mu¨ller
et al., 2009). However, there is evidenceNeuron 74, May 10,that GluN2A and GluN2B
subunits affect a-amino-3-
hydroxy-5-methyl-4-isoxazo-
lepropionic acid (AMPA)
receptor trafficking in oppo-
site ways, with GluN2A pro-
moting and GluN2B inhibiting
surface expression of GluA1
subunits.
In the realm of excitotoxic-
ity, it was previously demon-
strated that activation of
GluN2B-containing NMDA
receptors, at either synaptic
or extrasynaptic sites, leads
to excitotoxicity, whereas
activation of either synaptic
or extrasynaptic GluN2A-
contaning NMDARs pro-
motes neuronal survival and
is neuroprotective (Liu et al.,
2007). In this study, admin-
istration of glycine alone
or in the presence of a
GluN2B antagonist attenu-
ated ischemic brain damage.Understanding the mechanisms of
NMDAR-mediated excitotoxicity is para-
mount to the development of better neu-
roprotective tools in acute and chronic
conditions. While great strides had been
made, many of them by Hardingham’s
group, the intimate mechanisms of exci-
totoxicity had been missing. Although
the increased presence of GluN2B
subunits in extrasynaptic locations is still
a matter of debate, the role of these
subunits in NMDAR-mediated toxicity is
well supported by experimental evidence.
Huntington’s disease (HD) is one good
example in which the present findings
can open new venues for therapies.
Recent studies (Milnerwood et al., 2010;
Okamoto et al., 2009), partly promoted
by Hardingham’s previous work, have
demonstrated enhanced extrasynaptic
NMDAR-mediated activity in HD mouse
models and the effectiveness of meman-
tine (an NMDAR antagonist used as
a more selective extrasynaptic receptor
blocker) for the treatment of some HD
symptoms. Lynn Raymond’s laboratory
in Vancouver has demonstrated the
important role that the GluN2B subunit
plays in striatal cell death in HD. Expres-
sion of mutant huntingtin (htt) has been
hypothesized to alter striatal NMDAR
signaling (Raymond et al., 2011). In the2012 ª2012 Elsevier Inc. 427
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Previewsearly stages of the disease, studies in
HD genetic mouse models have shown
increased NMDAR-induced currents
(Starling et al., 2005). Importantly, this
increase appears to be mediated by
NMDAR-containing GluN2B subunits, as
enhanced currents and toxicity in cultured
neurons and acute slices are abolished
by ifenprodil or memantine (Kaufman
et al., 2012). Thus, experimental evidence
supports the idea that mutant htt
enhances cell death by modulating
GluN2B subunits. In agreement, dramatic
exacerbation of striatal neuronal loss was
reported when HD knockin mice were
crossed with GluN2B-overexpressing
mice (Heng et al., 2009). Does the pres-
ence and relative abundance of GluNR2B
subunits make neurons more vulnerable?
A recent study showed that medium-
sized spiny neurons (MSNs) of the indirect
striatal output pathway, i.e., the neurons
that are believed to be more affected in
the early stages of HD, express more
functional GluN2B-containing NMDARs
(Jocoy et al., 2011). In contrast, MSNs
of the direct pathway appear to ex-
press relatively greater levels of GluN2A
subunits and are less affected.
While these studies are indicative of
contrasting roles of NMDAR subunits, it
was not until the present work by Martel
et al. (2012) that the precise locus and
mechanisms have been unraveled. Based
on their findings, the GluN2B/PSD-95/
nNOS axis represents an attractive target
for therapeutic intervention. Indeed, as
the authors indicate, results from a series
of studies demonstrating antiexcitotoxic
effects of TAT-NR2B9c, PSD-95 knock-
down, or disruption of the PSD-95-nNOS428 Neuron 74, May 10, 2012 ª2012 Elsevierinterface can now be explained. In addi-
tion, the translational potential is great
and is supported by recent evidence
that administration of TAT-NR2Bc, even
hours after stroke, can prevent neuronal
damage and neurological deficits (Cook
et al., 2012). While the role of NO in
disease processes such as HD remains
to be established, neuroprotective or
neurotoxic effects can occur depending
on a number of factors (Deckel, 2001).
Although the new findings of Martel
et al. (2012) are revealing, more studies
will be necessary to understand how iden-
tity and location of GluN2 type subunits
at synaptic and extrasynaptic sites
contribute to excitotoxicity. In particular,
visualization of NMDAR surface mobility
in and out of the synapse in native con-
ditions will be extremely useful. For ex-
ample, using single-particle and single-
molecule tracking approaches, NMDAR
mobility has been shown to depend on
the identity of GluN2-type subunits, as
NMDARs containing GluN2B subunits
are less stable than those containing
GluN2A subunits (Groc et al., 2006). In
conclusion, the present contribution will
certainly become another classic in the
field of NMDAR-mediated neurotoxicity,
with far-reaching scientific and clinical
implications. As the GluN2 subunit saga
moves on, the ‘‘tail’’ of 2B or not 2B
remains an important component of the
question.
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